Joseph P. Lucia & Associates’s Myriad Genetics MYGN Stock Holding History

Joseph P. Lucia & Associates’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,000	Closed	-$40K	–	595
2020 Q4	$40K	Buy	+2,000	New	+$32.3K	0.03%	199
2020 Q3	–	Sell	-2,000	Closed	-$23K	–	318
2020 Q2	$23K	Hold	2,000	–	–	0.02%	235
2020 Q1	$29K	Buy	+2,000	New	+$42.3K	0.03%	203

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Joseph P. Lucia & Associates's MYGN Position: Q1 2021 in Review

Joseph P. Lucia & Associates sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 2,000 shares — an estimated $40K sold.

Joseph P. Lucia & Associates first reported a position in MYGN in Q1 2020 and held it in 3 quarters. The position peaked at $40K in Q4 2020. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

Joseph P. Lucia & Associates reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
Joseph P. Lucia & Associates sold 2,000 Myriad Genetics shares in Q1 2021, an estimated $40K.
Joseph P. Lucia & Associates first reported a position in Myriad Genetics in Q1 2020 and held it in 3 quarters.
Joseph P. Lucia & Associates's Myriad Genetics position peaked at $40K in Q4 2020.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on Joseph P. Lucia & Associates's 13F filing for Q1 2021, filed 23 Apr 2021.